Compare WDS & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WDS | ONC |
|---|---|---|
| Founded | 1954 | 2010 |
| Country | Australia | Switzerland |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.3B | 34.8B |
| IPO Year | N/A | N/A |
| Metric | WDS | ONC |
|---|---|---|
| Price | $15.57 | $303.78 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 12 |
| Target Price | N/A | ★ $369.50 |
| AVG Volume (30 Days) | ★ 987.6K | 270.8K |
| Earning Date | 08-18-2025 | 11-06-2025 |
| Dividend Yield | ★ 6.53% | N/A |
| EPS Growth | ★ 58.72 | N/A |
| EPS | ★ 1.54 | 0.58 |
| Revenue | ★ $13,781,000,000.00 | $4,972,687,000.00 |
| Revenue This Year | N/A | $895.40 |
| Revenue Next Year | N/A | $22.04 |
| P/E Ratio | ★ $10.18 | $521.15 |
| Revenue Growth | 9.53 | ★ 50.43 |
| 52 Week Low | $11.26 | $172.67 |
| 52 Week High | $17.70 | $385.22 |
| Indicator | WDS | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 44.25 | 36.89 |
| Support Level | $15.32 | $302.14 |
| Resistance Level | $15.73 | $310.88 |
| Average True Range (ATR) | 0.23 | 6.58 |
| MACD | -0.00 | -0.55 |
| Stochastic Oscillator | 51.42 | 15.69 |
Incorporated in 1954 and named after the small Victorian town of Woodside, Woodside's early exploration focus moved from Victoria's Gippsland Basin to Western Australia's Carnarvon Basin. First LNG production from the North West Shelf came in 1984. BHP Billiton and Shell each had 40% shareholdings before BHP sold out in 1994 and Shell sold down to 34%. In 2017 Shell sold its entire shareholding. Woodside is one of the most LNG-leveraged companies globally.
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.